Early Signs of Atherogenic Features in the HDL Lipidomes of Normolipidemic Patients Newly Diagnosed with Type 2 Diabetes.
Aged
Atherosclerosis
/ blood
Cholesterol, HDL
/ analysis
Coronary Disease
/ blood
Diabetes Mellitus, Type 2
/ blood
Fatty Acids
/ analysis
Female
Humans
Lipidomics
Lipoproteins, HDL
/ chemistry
Lysophosphatidylcholines
/ analysis
Magnetic Resonance Spectroscopy
Male
Middle Aged
Phosphatidylcholines
/ analysis
Phosphatidylethanolamines
/ analysis
Sphingomyelins
/ analysis
Triglycerides
/ analysis
HDL
coronary heart disease
lipidomics
type 2 diabetes
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
22 Nov 2020
22 Nov 2020
Historique:
received:
25
10
2020
revised:
20
11
2020
accepted:
20
11
2020
entrez:
3
12
2020
pubmed:
4
12
2020
medline:
7
5
2021
Statut:
epublish
Résumé
Cardiovascular disease (CVD) is the major cause of death in patients with type-2 diabetes mellitus (T2DM), although the factors that accelerate atherosclerosis in these patients are poorly understood. The identification of the altered quantity and quality of lipoproteins, closely related to atherogenesis, is limited in routine to a pattern of high triglycerides and low HDL-cholesterol (HDL-C) and in research as dysfunctional HDLs. We used the emerging NMR-based lipidomic technology to investigate compositional features of the HDLs of healthy individuals with normal coronary arteries, drug-naïve; recently diagnosed T2DM patients with normal coronary arteries; and patients with recent acute coronary syndrome. Patients with T2DM and normal serum lipid profiles even at diagnosis presented significant lipid alterations in HDL, characterized by higher triglycerides, lysophosphatidylcholine and saturated fatty acids; and lower cholesterol, phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, plasmalogens and polyunsaturated fatty acids, an atherogenic pattern that may be involved in the pathogenesis of atherosclerosis. These changes are qualitatively similar to those found, more profoundly, in normolipidemic patients with established Coronary Heart Disease (CHD). We also conclude that NMR-based lipidomics offer a novel holistic exploratory approach for identifying and quantifying lipid species in biological matrixes in physiological processes and disease states or in disease biomarker discovery.
Identifiants
pubmed: 33266469
pii: ijms21228835
doi: 10.3390/ijms21228835
pmc: PMC7700318
pii:
doi:
Substances chimiques
Cholesterol, HDL
0
Fatty Acids
0
Lipoproteins, HDL
0
Lysophosphatidylcholines
0
Phosphatidylcholines
0
Phosphatidylethanolamines
0
Sphingomyelins
0
Triglycerides
0
phosphatidylethanolamine
39382-08-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Biol Chem. 1995 Mar 17;270(11):5882-90
pubmed: 7890719
Wiley Interdiscip Rev Syst Biol Med. 2020 Jan;12(1):e1466
pubmed: 31646749
Diabetes Care. 1993 Feb;16(2):434-44
pubmed: 8432214
J Biol Chem. 2001 Feb 16;276(7):4804-11
pubmed: 11067853
Clin Chim Acta. 1999 Aug;286(1-2):145-61
pubmed: 10511289
J Biol Chem. 2000 Nov 24;275(47):36596-604
pubmed: 10964930
J Clin Exp Hepatol. 2015 Dec;5(4):320-8
pubmed: 26900274
Can J Biochem Physiol. 1959 Aug;37(8):911-7
pubmed: 13671378
Am J Clin Nutr. 2011 Feb;93(2):267-74
pubmed: 21123460
J Lipid Res. 2002 Aug;43(8):1264-74
pubmed: 12177170
Biochim Biophys Acta. 2015 Sep;1851(9):1254-61
pubmed: 26037829
BMJ. 1998 Mar 14;316(7134):823-8
pubmed: 9549452
Lipids Health Dis. 2010 Nov 09;9:130
pubmed: 21062475
J Lipid Res. 2000 Aug;41(8):1261-7
pubmed: 10946014
Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1843-9
pubmed: 17569880
Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2169-75
pubmed: 19762782
J Lipid Res. 2013 Nov;54(11):2950-63
pubmed: 23543772
Atherosclerosis. 1994 Oct;110 Suppl:S27-33
pubmed: 7857380
J Biol Chem. 1995 Nov 10;270(45):26910-7
pubmed: 7592936
Eur Heart J. 2016 Jan 14;37(3):267-315
pubmed: 26320110
N Engl J Med. 1998 Jul 23;339(4):229-34
pubmed: 9673301
Clin Nutr. 2010 Aug;29(4):492-500
pubmed: 19926177
J Lipid Res. 2004 Feb;45(2):337-46
pubmed: 14594995
J Lipid Res. 2015 Sep;56(9):1727-37
pubmed: 26117661
Diabet Med. 2009 Feb;26(2):142-8
pubmed: 19236616
Handb Exp Pharmacol. 2015;224:405-21
pubmed: 25522996
Metabolism. 2014 May;63(5):727-34
pubmed: 24636347
J Lipid Res. 2017 Jun;58(6):1238-1246
pubmed: 28420704
Int J Mol Sci. 2013 Apr 09;14(4):7716-41
pubmed: 23571495
J Am Coll Cardiol. 2017 Jul 11;70(2):179-181
pubmed: 28683965
Eur Heart J. 2010 Jan;31(2):149-64
pubmed: 19825813
Circulation. 2006 Mar 28;113(12):1556-63
pubmed: 16534013
Clin Chem. 2017 Jan;63(1):196-210
pubmed: 27879324
Atherosclerosis. 2003 Dec;171(2):287-93
pubmed: 14644399
Biochemistry. 2000 May 16;39(19):5712-21
pubmed: 10801321
Clin Sci (Lond). 2019 Nov 15;133(21):2221-2235
pubmed: 31722013
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
Curr Opin Biotechnol. 2017 Feb;43:34-40
pubmed: 27580257
J Am Coll Cardiol. 2006 Aug 15;48(4):715-20
pubmed: 16904539
Clin Chim Acta. 2014 Jun 10;433:34-8
pubmed: 24613518
Atherosclerosis. 2010 Jan;208(1):10-8
pubmed: 19570538
Curr Opin Lipidol. 2016 Jun;27(3):264-73
pubmed: 27031272
Atherosclerosis. 2007 Feb;190(2):352-8
pubmed: 16730730
Curr Opin Lipidol. 2019 Aug;30(4):314-319
pubmed: 31145119
Anal Chim Acta. 2019 Aug 27;1067:11-30
pubmed: 31047142
JCI Insight. 2020 Jan 16;5(1):
pubmed: 31830004
Curr Opin Lipidol. 2018 Aug;29(4):293-298
pubmed: 29846266
Curr Opin Lipidol. 2012 Feb;23(1):4-10
pubmed: 22123669
Metabolites. 2020 Apr 23;10(4):
pubmed: 32340170
J Thromb Haemost. 2018 May;16(5):933-945
pubmed: 29543379
Prog Lipid Res. 2017 Oct;68:37-56
pubmed: 28911967